Gleason 3+3 is technically cancer, but it sits at the very lowest end of the prostate cancer spectrum. It is the least aggressive form pathologists can diagnose, classified as Grade Group 1 in the modern five-tier system. For most men, it carries a very low risk of spreading and an excellent long-term prognosis, with disease-specific survival around 87% at 10 years even with conservative management alone.
That said, the question of whether Gleason 3+3 truly deserves the “cancer” label is one of the most active debates in urology today. Understanding both sides of that debate, and what the diagnosis means for your day-to-day life, can help put a biopsy result in perspective.
What Gleason 3+3 Means Under the Microscope
When a pathologist examines prostate biopsy tissue, they assign two pattern numbers from 1 to 5. The first number reflects the most common cell pattern they see; the second reflects the next most common. Those two numbers are added together for the Gleason score. A score of 3+3=6 means the pathologist saw only well-formed, individual glands throughout the sample. The cells are abnormal enough to qualify as cancerous, but they still organize themselves into recognizable gland structures rather than growing in the fused, irregular sheets that characterize higher-grade disease.
One important detail: scores of 2 through 5 are no longer assigned in modern practice. That means 6 is effectively the floor, not the middle of the scale. If your report says Gleason 6 or Grade Group 1, you have the lowest grade that exists in today’s system. Some patterns that were historically called a 6 have also been reclassified upward as 7, which means a modern Gleason 6 diagnosis carries a better prognosis than the same number would have implied decades ago.
Why Some Experts Want to Drop the Cancer Label
A growing group of researchers and clinicians argue that calling Gleason 3+3 “cancer” does more harm than good. Their reasoning centers on three points. First, pure Gleason pattern 3 has minimal metastatic potential. A 20-year follow-up study from the European Randomized Study of Screening for Prostate Cancer found that the amount of pattern 3 tissue in a biopsy had no independent effect on whether a man developed metastases, once any higher-grade patterns were accounted for. In other words, pattern 3 by itself does not appear to drive the disease forward.
Second, the cancer label causes real psychological harm. Hearing “you have cancer” triggers anxiety and depression, and some men rush into surgery or radiation they may not need. Third, the overdiagnosis and overtreatment of low-risk prostate cancer is a well-documented public health problem. Reclassifying Gleason 3+3 as something other than cancer, these experts argue, would reduce unnecessary treatment and the side effects that come with it.
Why It’s Still Classified as Cancer
The opposing camp, and the current consensus among pathology organizations, holds that Gleason 3+3 is a true malignancy. The cells have lost their normal basal layer, which is direct evidence that they can infiltrate surrounding tissue. They also share molecular and genetic features with higher-grade prostate cancers. Pattern 3 tissue can extend beyond the prostate gland and, in rare cases, can spread to distant sites.
There is also a practical problem with reclassification. Pattern 3 appears alongside higher-grade patterns (4 and 5) in many tumors. The pattern 3 tissue in a Gleason 3+4 tumor is morphologically identical to pattern 3 in a Gleason 3+3 tumor. If pattern 3 were declared benign, the entire grading system would collapse. You would logically have to exclude it from all scoring, leaving only combinations of patterns 4 and 5. The preferred strategy, according to the current consensus, is better education for clinicians and patients rather than relabeling malignant tissue as benign.
The Upgrading Problem
One reason Gleason 3+3 still warrants monitoring is that biopsies sample only a small portion of the prostate. A needle can miss higher-grade areas entirely. Studies examining the prostate after surgical removal have found significant upgrading rates: in one contemporary analysis, roughly 60 to 70% of men whose biopsies showed pure Gleason 3+3 turned out to have higher-grade disease in the final surgical pathology. That does not mean the biopsy was wrong. It means the biopsy captured one area while more aggressive cells existed elsewhere in the gland.
This is a key reason active surveillance protocols include repeat biopsies and imaging over time. The goal is to catch any upgrading early, while the cancer is still curable.
How Gleason 3+3 Is Managed
Active surveillance is the preferred initial approach for Gleason 3+3 across every major guidelines organization, including the American Urological Association, the National Comprehensive Cancer Network, the European Association of Urology, and the UK’s National Institute for Health and Care Excellence. This is not “doing nothing.” It is a structured monitoring plan designed to avoid treatment unless the cancer shows signs of progressing.
Protocols vary between institutions, but the typical active surveillance schedule includes periodic PSA blood tests (often every 6 to 12 months), digital rectal exams, prostate MRI scans, and repeat biopsies at defined intervals. If any of these tests suggest the disease has been upgraded to Grade Group 2 or higher, the plan shifts toward curative treatment such as surgery or radiation. Large-scale randomized trials have confirmed that men with Grade Group 1 disease who follow active surveillance have very low long-term risks of metastasis or death from prostate cancer.
Genomic Testing
Some doctors now use genomic tests to further refine risk in men with Gleason 3+3. These tests analyze the activity of a panel of genes in the biopsy tissue to generate a risk score that predicts how likely the cancer is to behave aggressively. A low genomic score can add confidence that active surveillance is the right choice. A higher score might prompt earlier repeat biopsy or closer monitoring. These tests are not universal, but they are increasingly used in clinical practice, particularly when there is uncertainty about whether to stay on surveillance or consider treatment.
Long-Term Outlook
The survival statistics for Gleason 3+3 are reassuring. In a pooled analysis of 828 men with localized prostate cancer managed conservatively (with hormonal therapy added only if symptoms developed later), those with low-grade tumors had disease-specific survival of 87% at 10 years. Their overall survival closely matched what would be expected for men of the same age without prostate cancer. These numbers come from an era before modern active surveillance protocols, MRI-guided biopsies, and genomic testing, all of which have improved the ability to detect progression early.
For the majority of men diagnosed with Gleason 3+3, the cancer will never threaten their life. The real challenge is living with the knowledge that abnormal cells exist in the prostate while resisting the urge to treat something that, in most cases, is best left alone and simply watched.